Actively Recruiting
Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA
Led by Centre Antoine Lacassagne · Updated on 2025-04-13
238
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of liquid biopsy to detect molecular abnormalities in patients with advanced malignant solid tumors managed by the Multidisciplinary Molecular Biology Meeting. The study compares liquid biopsy results to the current gold standard, solid biopsy, to assess diagnostic accuracy. This research is led by Centre Antoine Lacassagne and focuses on understanding how well liquid biopsy can identify tumor genetics. Participants will have a blood sample of 36 mL taken for molecular analysis via liquid biopsy. This is done alongside the routine molecular testing performed on tumor tissue from either archived samples or biopsiable lesions. The study involves one main experimental procedure where both liquid and solid biopsies are analyzed to compare their sensitivity and specificity. During the study, researchers will measure how sensitively and specifically the liquid biopsy detects molecular abnormalities compared to the solid biopsy within one month. They will also assess failure rates of molecular screening, predictive clinical factors, unexploitable result rates, and the time needed to obtain test results. Participants must be followed with standard consent and social security coverage, and the study will monitor patient outcomes and sample analyses throughout the participation period.
CONDITIONS
Brief Title
Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Over 18 years old.
- Advanced-stage malignant solid tumor managed in a non-curative context.
- Eligible for Multidisciplinary molecular biology meeting with available archived tumor material or a biopsiable tumor lesion.
- Performance status of 0 or 1.
- Able to read, write, and understand French.
- Has read the information sheet and signed the informed consent.
- Has social security coverage.
You will not qualify if you...
- Previous or concurrent cancer diagnosed or treated within the last 5 years, except certain in situ carcinomas and treated skin carcinomas.
- Severe or uncontrolled systemic disease.
- Any condition that makes the patient unable to comply with study follow-up and procedures.
- Considered a vulnerable person, including pregnant or breastfeeding women, persons deprived of liberty, hospitalized without consent, admitted to healthcare or social institutions for reasons other than research, or adults unable to give consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 month
Participants have a blood sample taken for molecular analyses as part of the study’s diagnostic procedures, in addition to routine tumor sample analyses.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Centre Antoine Lacassagne
Nice, France, 06189
Actively Recruiting
Research Team
S
Study coordinator
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here